Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
The purpose of this study is to assess efficacy and safety in combination of resminostat and sorafenib in Asian patients with advanced HCC previously untreated with systemic chemotherapy.
Hepatocellular Carcinoma
DRUG: Resminostat|DRUG: Sorafenib
Phase 1 : Number of participants with dose limited toxicities as measure of safety and tolerability, 6 months|Phase 2 : Time To Progression (TTP), 12 months
The purpose of this study is to assess efficacy and safety in combination of resminostat and sorafenib in Asian patients with advanced HCC previously untreated with systemic chemotherapy.